Clinical Report: Recent Developments in Nanoparticle-Based Drug Delivery Systems
Overview
This review discusses the role of nanoparticle-based drug delivery systems in modifying the tumor immune microenvironment in triple-negative breast cancer (TNBC). It highlights the challenges posed by TIME heterogeneity.
Background
The tumor immune microenvironment (TIME) is crucial in determining the immunogenicity of tumors and their response to therapies. In triple-negative breast cancer (TNBC), which lacks specific hormonal targets and exhibits high heterogeneity, understanding and manipulating the TIME is essential.
Data Highlights
No numerical data provided in the source material.
Key Findings
TIME consists of various immune and stromal cells that influence tumor behavior and treatment response.
Effector T/NK cells and immunosuppressive populations determine whether tumors are 'cold' or 'hot'.
Nanocarriers can exploit features of the TIME, such as hypoxia and acidity, for targeted drug delivery.
Challenges in developing effective nano-immunotherapies include TIME heterogeneity and the formation of a protein corona around nanoparticles.
Clinical Implications
Understanding the dynamics of the TIME in TNBC is essential for developing targeted therapies.
Conclusion
Further research is needed to overcome existing translational barriers in nanoparticle-based drug delivery systems.
